Research Applications
Cardiac Repair
Phase 1/2 clinical trials by RegeneRx for myocardial infarction recovery. Reduces infarct size, improves ejection fraction, activates cardiac progenitor cells.
Wound Healing
Clinical trials for dermal wound healing and corneal injuries. Accelerates healing through cell migration, angiogenesis, and collagen deposition.
Ophthalmology
RGN-259 (Tβ4 eye drops) completed Phase 3 clinical trials for dry eye disease and neurotrophic keratopathy, showing improved corneal healing and symptom relief.
Musculoskeletal Repair
Preclinical studies demonstrate accelerated tendon, ligament, and muscle repair through satellite cell activation and collagen organization.
Mechanism of Action
Tβ4 sequesters G-actin monomers through the LKKTETQ domain, regulating actin polymerization dynamics essential for cell migration, division, and morphological changes. It promotes angiogenesis through VEGF and Ang1/Tie2 upregulation. Anti-inflammatory effects via NF-κB inhibition reduce tissue damage. Akt/protein kinase B activation provides cardioprotection and cell survival signaling. Tβ4 also activates resident stem/progenitor cells in cardiac, skeletal muscle, and epithelial tissues.
Biological Pathways
Akt/mTOR survival pathway. VEGF/Ang1 angiogenic signaling. HIF-1α hypoxia response. NF-κB inflammatory regulation. Wnt/β-catenin stem cell activation.
Dosage Information
Calculation Results
Syringe Fill Level (100u syringe)
Protocols
No protocols featuring this peptide yet.
Browse All ProtocolsStability & Storage
Tβ4 is supplied as lyophilized powder. Store at -20°C for long-term stability. The N-terminal acetylation protects against aminopeptidase degradation. Reconstitute with bacteriostatic water, store at 2-8°C, use within 21 days. Susceptible to methionine oxidation.
Side Effects & Precautions
Generally well-tolerated in clinical trials. Mild injection site reactions. Transient lightheadedness. Theoretical cancer concern due to pro-migratory and pro-angiogenic properties, though no evidence from clinical studies. Limited long-term human safety data.
Research Use Only. This information is for educational and research purposes only. Not intended for medical advice or self-medication.
Regulatory Status
Investigational. Phase 2/3 clinical trials completed for ophthalmological and cardiac applications (RegeneRx Biopharmaceuticals). Not FDA-approved. WADA-prohibited under S2 category.
Research Studies
Thymosin Beta 4: A Multi-Functional Regenerative Peptide
Goldstein AL, Hannappel E, Sosne G, Kleinman HK.
Thymosin β4 Activates Cardiac Progenitor Cells
Smart N, Risebro CA, Melville AA, et al.
Thymosin β4 in Wound Healing
Malinda KM, Sidhu GS, Mani H, et al.






